Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of Concurrent Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Patients With Locally-advanced Esophageal Squamous Cell Cancer

NCT05621707 is registered in ClinicalTrials.gov with Shanghai Chest Hospital as lead sponsor.

NCT NCT05621707
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05621707 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of Concurrent Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Patients With Locally-advanced Esophageal Squamous Cell Cancer
Lead sponsor
Shanghai Chest Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 2, 2022
Completion date
October 31, 2026
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy, concurrent chemoradiotherapy, esophageal squamous cell carcinomas, immunotherapy